ANVS

Annovis Bio (ANVS)

About Annovis Bio (ANVS)

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Details

Daily high

$4.24

Daily low

$3.76

Price at open

$4.15

52 Week High

$5.60

52 Week Low

$1.11

Market cap

109.5M

Dividend yield

0.00%

Volume

712,792

Avg. volume

4.2M

P/E ratio

-2.78

Annovis Bio News